Rare liver disease wins mount as Mirum’s PFIC trial meets endpointClinical Trials, R&D, TherapeuticsMirum Pharmaceuticals announced that Livmarli oral solution met its primary endpoint in the Phase III MARCH study in young patients with progressive familial intrahepatic cholestasis. Read more October 25, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/10/Abdomincalscan-BioSpace.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-25 09:04:422022-10-25 09:04:42Rare liver disease wins mount as Mirum’s PFIC trial meets endpoint
